Open access
Oct 2026
Real-World Renal and Metabolic Outcomes of SGLT-2 Inhibitor Therapy in Patients with Type 2 Diabetes Mellitus
In routine care, SGLT2 inhibitor initiation was followed by changes in glycaemic, haematological, uric acid and albuminuria parameters that were similar in direction to those reported in randomised trials; the uncontrolled design and incomplete UACR data preclude causal inference.
Öykü Ünsal, Huseyin Dongelli, M. Ünal et al.
· Journal of Clinical Medicine · 0 citations